# US 2015/0148529 A1 · Nucleic acid complex and nucleic acid-polysaccharide complex

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148529 A1
- Document ID: US20150148529A1
- Status: Published application
- Kind: A1
- Application number: 14/408,577
- Filed: 2013-06-19
- Published: 2015-05-28
- Earliest claimed: 2012-06-20
- Assignees: Japan Science and Technology Agency
- Applicants: Japan Science and Technology Agency
- Inventors: Kazuo Sakurai; Shin-ichi Mochizuki; Motoko Tanaka; Sadaharu Higuchi
- Web page: https://patentgrep.com/patent/US20150148529A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 31/711: Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- C07H 21/00: Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/3519: Fusion with another nucleic acid
- C12N 2320/51: modulating the chemical stability, e.g. nuclease-resistance
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

As a means for solving the problem of providing a nucleic acid conjugate that does not undergo degradation at a DNA-RNA bonding site even in vivo, provided is a nucleic acid conjugate comprising a single-stranded DNA and a double-stranded RNA, wherein the 3′ position of the 3′-terminal deoxyribonucleotide residue of the single-stranded DNA is bonded to the 5′ position of the 5′-terminal ribonucleotide residue of one of the ribonucleotide strands of the double-stranded RNA, and the hydroxyl group at the 2′ position of the 5′-terminal nucleotide of the ribonucleotide strand, which is bonded to the single-stranded DNA, is substituted with an alkoxy group or a halogen atom, and/or the phosphate diester group between the 3′ position of the first ribonucleotide bonded to the single-stranded DNA and the 5′ position of the adjacent ribonucleotide is substituted with any of phosphorothioate group, dithiophosphate diester group and trithiophosphate diester group.

## Claims

### Claim 1

A nucleic acid conjugate comprising a single-stranded DNA and a double-stranded RNA, wherein the 3′ position of the 3′-terminal deoxyribonucleotide residue of the single-stranded DNA is bonded to the 5′ position of the 5′-terminal ribonucleotide residue of one of the ribonucleotide strands of the double-stranded RNA, and the hydroxyl group at the 2′ position of the 5′-terminal nucleotide of the ribonucleotide strand, which is bonded to the single-stranded DNA, is substituted with an alkoxy group or a halogen atom.

### Claim 2

A nucleic acid conjugate comprising a single-stranded DNA and a double-stranded RNA, wherein the 3′ position of the 3′-terminal deoxyribonucleotide residue of the single-stranded DNA is bonded to the 5′ position of the 5′-terminal ribonucleotide residue of one of the ribonucleotide strands of the double-stranded RNA, and the phosphate diester group between the 3′ position of the first ribonucleotide bonded to the single-stranded DNA and the 5′ position of the adjacent ribonucleotide is substituted with any of phosphorothioate group, dithiophosphate diester group, dithiophosphate diester group and trithiophosphate diester group.

### Claim 3 (depends on 1)

The nucleic acid conjugate according to claim 1, wherein the number of nucleotides in the single-stranded DNA is not less than 10.

### Claim 4 (depends on 1)

The nucleic acid conjugate according to claim 1, wherein the single-stranded DNA is a polydeoxyadenine strand.

### Claim 5 (depends on 1)

The nucleic acid conjugate according to claim 1, wherein at least some of the phosphate diester groups of the single-stranded DNA are substituted with any of phosphorothioate group, dithiophosphate diester group and trithiophosphate diester group.

### Claim 6 (depends on 5)

The nucleic acid conjugate according to claim 5, wherein at least 50% or more of the phosphate diester groups of the single-stranded DNA are substituted with any of phosphorothioate group, dithiophosphate diester group and trithiophosphate diester group.

### Claim 7 (depends on 1)

The nucleic acid conjugate according to claim 1, wherein the double-stranded RNA is an siRNA.

### Claim 8 (depends on 7)

The nucleic acid conjugate according to claim 7, wherein the siRNA is a 21-mer or 27-mer siRNA.

### Claim 9 (depends on 7)

The nucleic acid conjugate according to claim 7, wherein one or more target genes of the siRNA are genes expressed in Dectin-1-expressing cells.

### Claim 10 (depends on 1)

A nucleic acid-polysaccharide complex, wherein the single-stranded DNA portion of one molecule of the nucleic acid conjugate according to claim 1 and two molecules of a polysaccharide having a β-1,3-glucan backbone form a triple helix structure.

### Claim 11 (depends on 10)

The nucleic acid-polysaccharide complex according to claim 10, wherein the polysaccharide having a β-1,3-glucan backbone is schizophyllan.

### Claim 12 (depends on 10)

A pharmaceutical composition comprising the nucleic acid-polysaccharide complex according to claim 10.

### Claim 13

A method of enhancing the stability of a nucleic acid conjugate to a ribonuclease, wherein:
the nucleic acid conjugate comprises a single-stranded DNA and a double-stranded RNA; and
the 3′ position of the 3′-terminal deoxyribonucleotide residue of the single-stranded DNA is bonded to the 5′ position of the 5′-terminal ribonucleotide residue of one of the ribonucleotide strands of the double-stranded RNA;
the method comprising substituting the hydroxyl group at the 2′ position of the 5′-terminal nucleotide of the ribonucleotide strand, which is bonded to the single-stranded DNA, by an alkoxy group or a halogen atom to stabilize the nucleic acid conjugate.

### Claim 14

A method of enhancing the stability of a nucleic acid conjugate to a ribonuclease, wherein:
the nucleic acid conjugate comprises a single-stranded DNA and a double-stranded RNA; and
the 3′ position of the 3′-terminal deoxyribonucleotide residue of the single-stranded DNA is bonded to the 5′ position of the 5′-terminal ribonucleotide residue of one of the ribonucleotide strands of the double-stranded RNA;
the method comprising substituting the phosphate diester group between the 3′ position of the first ribonucleotide bonded to the single-stranded DNA and the 5′ position of the adjacent ribonucleotide by any of phosphorothioate group, dithiophosphate diester group and trithiophosphate diester group to stabilize the nucleic acid conjugate.

### Claim 15 (depends on 2)

The nucleic acid conjugate according to claim 2, wherein the number of nucleotides in the single-stranded DNA is not less than 10.

### Claim 16 (depends on 2)

The nucleic acid conjugate according to claim 2, wherein the single-stranded DNA is a polydeoxyadenine strand.

### Claim 17 (depends on 2)

The nucleic acid conjugate according to claim 2, wherein at least some of the phosphate diester groups of the single-stranded DNA are substituted with any of phosphorothioate group, dithiophosphate diester group and trithiophosphate diester group.

### Claim 18 (depends on 17)

The nucleic acid conjugate according to claim 17, wherein at least 50% or more of the phosphate diester groups of the single-stranded DNA are substituted with any of phosphorothioate group, dithiophosphate diester group and trithiophosphate diester group.

### Claim 19 (depends on 2)

The nucleic acid conjugate according to claim 2, wherein the double-stranded RNA is an siRNA.

### Claim 20 (depends on 19)

The nucleic acid conjugate according to claim 19, wherein the siRNA is a 21-mer or 27-mer siRNA.

### Claim 21 (depends on 8)

The nucleic acid conjugate according to claim 8, wherein one or more target genes of the siRNA are genes expressed in Dectin-1-expressing cells.

### Claim 22 (depends on 19)

The nucleic acid conjugate according to claim 19, wherein one or more target genes of the siRNA are genes expressed in Dectin-1-expressing cells.

### Claim 23 (depends on 20)

The nucleic acid conjugate according to claim 20, wherein one or more target genes of the siRNA are genes expressed in Dectin-1-expressing cells.

### Claim 24 (depends on 2)

A nucleic acid-polysaccharide complex, wherein the single-stranded DNA portion of one molecule of the nucleic acid conjugate according to claim 2 and two molecules of a polysaccharide having a β-1,3-glucan backbone form a triple helix structure.
